Oxidative stress is considered to reflect an imbalance between the systemic manifestation of reactive oxygen and nitrogen species (RONS) and a biological system's ability to readily detoxify the reactive intermediates or to repair the resulting damage. RONS are not only harmful agents that cause oxidative damage in pathologies; they also have important roles as regulatory agents in a range of biological phenomena. They are normally generated as by-products of oxygen metabolism; however, environmental stressors (i.e., ultraviolet radiation, ionizing radiations, pollutants, heavy metal, and xenobiotics) contribute to greatly increase RONS production. Several antioxidants have been exploited in recent years for their actual or supposed beneficial effect against oxidative stress, but to date, none has been approved for any indication because they have not met the criteria of efficacy for drug approval. The present review discusses the concept of oxidative stress, how to measure it, how to prevent it, and its occurrence in different organ systems with special reference to the lower urinary tract.
Introduction
Generally, oxidative stress has been considered to reflect an imbalance between the systemic manifestations of reactive oxygen (ROS) and nitrogen (RNS) species (RONS) and a biological system's ability to readily detoxify the reactive intermediates or to repair the resulting damage. It has been more distinctly defined as 'An imbalance between oxidants and anti-oxidants in favour of the oxidants, leading to a disruption of redox signalling and control and/or molecular damage' [1] . Oxidative stress is often considered to be the cause and/or contributor of diseases and, as pointed out by Ghezzi et al. [2] 'Today it is a challenge to find a disease for which a role of oxidative stress has not been postulated'.
ROS is often used as a generic term, but Murphy et al. [3] emphasised that all ROS molecules are not the same and the term encompasses a diverse range of species, including superoxide, hydrogen peroxide (H 2 O 2 ), nitric oxide (NO), peroxynitrite, hypochlorous acid, singlet oxygen, and the hydroxyl radical. Each of these molecules is a distinct chemical entity with its own reaction preferences, kinetics, rates, site of production and degradation, and diffusion characteristics in biological systems. The biological impacts of ROS depend critically on the particular molecule(s) involved, and on the microenvironment and physiological or pathological context in which it is being generated [3] .
The present review discusses the concept of oxidative stress, how to measure it, how to prevent it, and its occurrence in different organ systems with special reference to the lower urinary tract (LUT).
What is oxidative stress?
A free radical can be defined as an atom or molecule containing one or more unpaired electrons in the valency shell or outer orbit and is capable of independent existence. The odd number of electron(s) of a free radical makes it unstable, short lived, and highly reactive. Because of their high reactivity, they can abstract electrons from other compounds to attain stability. Thus, the attacked molecule loses its electron and becomes a free radical itself, beginning a chain reaction cascade that finally damages the living cell. ROS include free radicals such as superoxide anion and hydroxyl radicals, as well as non-radicals, such as H 2 O 2 [4, 5] , and are derived from both endogenous sources (e.g., nicotinamide adenine dinucleotide phosphate [NADPH] oxidase [NOX] , xanthine oxidase, uncoupled NO synthase, cyclooxygenases mitochondrial respiratory chain), and from the environment (ionizing radiation, pollutants, and heavy metals, xenobiotics). NOX is one of the most important sources of oxidants in cells [6] , but mitochondria may also produce oxidants under certain conditions. The concept behind oxidative stress as cause of disease is that the metabolism of molecular oxygen by the cell results in the production of ROS. For this reason, organisms have developed antioxidant defence systems to eliminate ROS. These include enzymes, such as superoxide dismutase (SOD) glutathione peroxidase, and catalase, and low-molecularweight antioxidants (vitamin E, vitamin C and glutathione [GSH] ).
It is now commonly accepted that macromolecule oxidation in response to RONS is associated with a variety of pathologies, and that NO is a key regulator of redox signalling. RNS has pathophysiological significance and can elicit various modifications of macromolecules and lead to nitrative or nitro-oxidative stress. Under physiological conditions, NO concentrations are usually nanomolar and therefore serve as a 'sink' for the picomolar concentrations of superoxide, thereby preventing oxidative mechanisms. Under certain pathophysiological conditions, superoxide and NO concentrations rise, and nitrosative and nitrative stress almost always precede oxidative stress [7] .
RONS are not only harmful agents that cause oxidative damage in pathologies; they also have important roles as regulatory agents in a range of biological phenomena [8, 9] . There is growing recognition that many RONS are important mediators in a range of biological processes, e.g. signalling. Redox signalling is essential for the maintenance of homeostasis, at the level of the organelle, the cell, the tissue and organ, and the organism. The mechanisms that control the generation and the degradation of RONS, composed only of oxygen, nitrogen and hydrogen, virtually regulate most of the essential cell functions: proliferation, differentiation, death through apoptosis, and metabolism. Indeed, many enzymes including kinases and phosphatases, synthases of all types, along with ion exchangers, transporters and channels, docking and structural proteins, are either affected by oxidation and reduction of cysteine residues, or by posttranslational modifications due to RONS.
Measures of oxidative stress
To investigate oxidative and nitro-oxidative stress in human and in live animal models, different biomarker assays have been developed [5, 10] . Key biomarkers are used to assess lipid peroxidation and NO/NO 2 signalling, thereby stressing the necessity to analyse several biomarkers in relation to the overall (aerobic) metabolism and health condition of patients. Lipid peroxidation plays a role in the pathogenesis of many diseases with tissue damage and malondialdehyde (MDA), a product of lipid peroxidation, has been used as a significant marker in assessing oxidative stress for a long time. In a sample of randomly selected group of 213 persons, Nielsen et al. [11] found an independent effect of gender, but not of age. Daily smokers had a slightly higher average concentration of MDA than non-smokers, and MDA correlated with daily exposure to cigarette smoke. A positive correlation was also shown between MDA and weekly alcohol consumption. Within-subject and day-to-day variations of MDA indicated that the potential of MDA as a biomarker for individuals is questionable, but did not exclude that it could be of value on a group basis.
Oxidative DNA damage is an inevitable consequence of cellular metabolism, with a propensity for increased levels following toxic insult [12, 13] . 8-hydroxy-2 0 -deoxyguanosine (8-OHdG) is one of the most common markers of oxidative DNA damage. It is not unreasonable to speculate that given the multiple pathways for its repair, oxidative DNA damage is likely to play an important role in disease. Indeed, it seems that ROS and oxidative DNA damage are omnipresent in disease. However, the mere presence of damage is not proof of a causative link, although there seems to be a close link between ROS formation and oxidative DNA damage. As emphasised by Cook et al. [12] , a great deal of work remains to be completed in defining the exact roles of oxidative DNA damage in the pathogenesis of disease.
Whereas a panel of >70 biomarkers of oxidative stress, in particular with respect to lipid oxidation and peroxidation, has been developed, there is still a lack of validated biomarkers to study the outcomes of nitro-oxidative stress or better, its status, which is often reversible and precedes oxidation in many pathological conditions [5, 10] . Such new validated biomarkers should also allow the investigation of the real and true role and involvement of nitro-oxidative stress and oxidative stress during the progression of diseases, as well as the evaluation of the potential benefit of pharmacological interventions aimed at fighting it.
It is important to distinguish between the measurement of RONS themselves and the assessment of the damage that these RONS cause. Biomarkers of oxidative damage such as protein carbonyls, lipid peroxidation products, or breakdown products of damaged DNA are often used, particularly in vivo, to infer production of RONS such as the hydroxyl radical. However, the link between the accumulation of a marker for oxidative damage and production of a particular RONS is indirect, because a change in clearance can dramatically alter the level of the marker with no change in production of a given ROS. It is unlikely that a single biomarker will ever give a complete picture of oxidative damage in vivo, as different types of damage to lipids, the proteome or the genome will lead to distinct patterns of accumulation of biomarkers, whilst interventions such as antioxidants will also affect the accumulation of biomarkers differentially. Hence, whatever biomarkers are used they are not necessarily a simple single marker of overall oxidative 528 © 2017 The Authors BJU International © 2017 BJU International damage, but will each respond differently to alternative types of damage and interventions.
Antioxidants
There is a continuous generation of RONS and organisms have evolved complex enzymatic defences against the attacks of free radicals, the 'antioxidant defence' [14] . To restore the imbalance between oxidants and antioxidant in oxidative stress, it seems logical to enhance this defence. However, despite many preclinical and clinical studies indicating a beneficial effect of antioxidants in several disease conditions, randomised clinical trials have failed to provide the evidence of efficacy required for drug approval. Antioxidant treatment has been shown to sometimes even worsen the disease and agents acting by scavenging RONS might not only prevent the detrimental effects, but also interfere with essential signalling roles of RONS. To date, no antioxidant has been recommended or offered by healthcare systems or been approved as therapy by regulatory agencies that base their decisions on evidence-based medicine [2] . The levels of evidence required to claim causality in preclinical research on oxidative stress is weak, which is attributable to the oversimplification associated with oxidative stress theory of disease. RONS have a complex metabolism and are generated by different enzymes at diverse sites and at different times, and it has been suggested that future research may need to focus on specific oxygen-toxifying pathways rather than on non-specific RONS scavengers [2] . It is obvious that to establish a causal relationship between RONS and LUT disorders, sophisticated investigations are required. Identification of specific targets for treatment is essential if treatment with antioxidants can be successful [6] .
Oxidative stress in various organ systems
Many studies have been devoted to the occurrence of and consequences of oxidative stress in various organ/systems such as cancer [15] , CNS [16, 17] , cardiovascular system [18] [19] [20] , lung [21] [22] [23] , and kidney [24, 25] . Involvement in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis have been demonstrated, and the developments in the search for effective therapeutic agents that target redox homeostasis, such as inhibitors of NOXs that are likely candidates for clinical use, have recently been discussed [17] .
Oxidative stress in the cardiovascular system has been the focus of many investigations [20] . The metabolic syndrome and specifically conditions such as diabetes and hypercholesterolaemia are considered main risk factors for cardiovascular disease. Hypercholesterolaemia has been shown to have direct negative effects on the myocardium itself, in addition to the development of atherosclerosis. As hypercholesterolaemia affects the global cardiac gene expression profile, amongst many other factors, it results in increased myocardial oxidative stress, mitochondrial dysfunction and inflammation-triggered apoptosis, all of which may account for myocardial dysfunction and increased susceptibility of the myocardium to infarction [26] . Similar effects may be relevant for the generation of bladder dysfunction.
Oxidative stress and LUT pathology
Many disorders may be associated with oxidative stress and LUT dysfunction. Metabolic syndrome and LUT dysfunction often occur together, which does not mean that there is a causal link between the entities. Metabolic syndrome describes a combination or clustering of several metabolic abnormalities, including central obesity, dyslipidaemia, hypertension, insulin resistance with compensatory hyperinsulinaemia, and glucose intolerance, all risk factors for cardiovascular disease [27] . Increasing evidence from several clinical studies has suggested a possible positive relationship between metabolic syndrome and its components and the occurrence and progression of LUTS [28] . Amongst the many factors suggested contributing to the relationship is cellular oxidative stress. Thus, excessive formation of the superoxide anion in adipose tissue may be an important interfering factor diverting the signalling of NO and other ROS and RNS in obesity, resulting in metabolic dysfunction of adipose tissue over time [29] .
Specific disorders where oxidative stress has been considered to have a role in LUT pathology include diabetes, obesity, bladder ischaemia, and BPH. However, what is really the role of RONS for LUT pathologies? Are they the primary cause or is their occurrence secondary, reflecting 'collateral damage'?
Animal models
One of the main ROS is superoxide. Mice with a mutation in the Immp2 l gene, which leads to high superoxide ion production [30] , showed bladder dysfunction [31] . In young male mutant mice emptying abnormalities were seen on conscious cystometry. Old female mutant mice had increased detrusor activity, a higher bladder-to-body weight ratio and a lower maximum detrusor contractile response to carbachol than wild-type controls. It was speculated that these mice could be a natural model of oxidative stress and consequent low bioavailability of NO, and provide an interesting tool in which to study the role of these conditions on bladder function. Unfortunately, no further studies with this model have been conducted.
If a specific ROS is used locally to directly induce bladder overactivity, there should be less question about cause and effect. Masuda et al. [32] 
Diabetes
It is widely accepted that diabetes is associated with oxidative stress. In a streptozotocin (STZ)-induced diabetic rat model (type 1 diabetes), Beshay and Carrier [33] measured the antioxidant scavenging enzymes (catalase and SOD)-like activity and the levels of the thiobarbituric acid reactive substances, as a marker of lipid peroxidation. They also examined the levels of inducible NO synthase (NOS) and apoptosis in the bladders. A diuretic control group was included. A statistically significant reduction in the catalaselike activity was found in the bladders from the diabetic group, but the difference in the SOD-like activity was not statistically significant amongst the groups. The thiobarbituric acid reactive substances levels were significantly greater in the diabetic compared with other groups. Immunohistochemical and apoptosis studies showed a statistically significant increased number of inducible NOS-positive and apoptotic cells in the diabetic bladder smooth muscle. The authors concluded that oxidative stress occurred in the bladders of the STZ-diabetic rats and was not mediated by diuresis and that oxidative damage of the smooth muscle cells may be a contributory factor in diabetic cystopathy. STZ-induced diabetes is a systemic disorder, not restricted to the bladder. Thus, the findings may reflect a local manifestation of a disease associated with systemic oxidative stress that contributes to diabetic cystopathy by affecting more bladder structures than detrusor smooth muscle cells.
Obesity
Diabetes and obesity often occur together and share common urological complications [34] , and clinically obesity may be a major contributing factor for LUTS [35] . Obese animals exhibit cystometric alterations such as increases in the frequency of voiding and non-voiding contractions [36] [37] [38] [39] , but the link between obesity-associated bladder dysfunction and oxidative stress has not been widely studied. Assuming that oxidative stress is involved in the pathogenesis of bladder dysfunction in obese animals, Alexandre et al. [39] evaluated whether oral intake of the antioxidant, resveratrol (a polyphenol present in many plant-based foods, such as grapes, peanuts and berries) could ameliorate overactive bladder in high-fat fed mice. Resveratrol inhibits NOXmediated production of ROS by down-regulating the expression and activity of the oxidase [40] . Male C57BL6 mice, fed with standard chow or high-fat diet to induce obesity, received a 2-week therapy with resveratrol. Weight and metabolic profile, together with cystometry and in vitro bladder contractions were evaluated. Measurements of biomarkers of oxidative stress (gp91phox and SOD1 mRNA expressions) and ROS in bladder tissues were performed. Obese mice exhibited increases in body weight and epididymal fat mass, which were significantly reduced by oral treatment with resveratrol. The obese mice showed increases in non-voiding contractions, post-voiding pressure and voiding frequency that were reversed by resveratrol treatment. The expression of oxidative stress markers in bladder tissues were markedly higher in obese mice compared with the lean group. In addition, ROS levels in bladder tissues and serum lipid peroxidation were markedly higher in obese compared with lean mice, all of which were reduced by resveratrol treatment. In the lean group, resveratrol had no effect on any parameter evaluated. It was concluded that resveratrol reduced systemic and bladder oxidative stress, and the authors suggested that resveratrol treatment could be an option to prevent obesity-associated overactive bladder. As mentioned earlier, to claim causality based on markers of oxidative stress is uncertain. In addition, antioxidants may not only prevent the detrimental effects of ROS, but also interfere with essential signalling roles of ROS. Even if resveratrol had no effect on normal animals, the translational impact of the findings should not be overestimated.
Bladder ischaemia
Evidence from clinical and basic research suggests that atherosclerosis in both sexes can induce a reduction of bladder blood flow, leading to chronic ischaemia of the bladder [41] . Chronic bladder ischaemia and repeated ischaemia/reperfusion during a micturition cycle might produce oxidative stress, leading to denervation of the bladder and the expression of tissue damaging molecules in the bladder wall [43] . Nomiya et al. [42] characterised, in a rat model, the effects of atherosclerosis-induced chronic bladder ischaemia on bladder function and associated changes in oxidative stress markers and pro-inflammatory cytokines. Adult Sprague-Dawley male rats were divided into three groups (arterial endothelial injury: AI, sham, na€ ıve). The AI group underwent endothelial injury of the iliac arteries (balloon distension) and received a 2% cholesterol diet. The sham group underwent sham operation and received a 2% cholesterol diet. The na€ ıve group (n = 12) received a regular diet. After 8 weeks, cystometrograms without anaesthesia or restraint were performed. In bladders from each group, oxidative stress markers (8-OHdG and MDA) and proinflammatory cytokines (interleukin 8-like cytokine C-X-C motif chemokine ligand 1/cytokine-induced neutrophil chemoattractant 1 [CXCL1/CINC-1], TNF-a, and interleukin 6) were quantified. Histological examination of the iliac arteries was also performed. At 8 weeks, the body and bladder wet weights were not significantly different amongst 530 © 2017 The Authors BJU International © 2017 BJU International the three groups. The micturition interval in the AI group decreased significantly compared with those in the other two groups, but maximum pressure during micturition did not change. The iliac arteries in the AI group revealed thickening of intima, as well as diffuse media fibrosis at the sites of balloon injury. The levels of oxidative stress markers and proinflammatory cytokines were significantly higher in the AI than in the other groups. It was concluded that oxidative stress and inflammation may be key factors in the development of bladder dysfunction in atherosclerosisinduced chronic bladder ischaemia. In this model, oxidative stress may be involved at several levels: i) at the lesion leading to the atherosclerotic obstruction, ii) at the microvasculature where changes will lead to iii) ischaemic remodelling of the bladder wall. However, if oxidative stress is the main initiating factor is unclear.
There are many agents showing protective effects against oxidative stress induced by ischaemia/reperfusion bladder injuries and chronic bladder ischaemia, e.g., melatonin, coenzyme Q10, eviprostat, vitamin E, and edaravone [44] , but whether the effects of these drugs can be attributed only to reduction of oxidative stress remains to be established.
BPH
Plasma markers of oxidative stress are increased in men with BPH, but it is unclear whether oxidative stress and/or oxidative DNA damage are causative in the pathogenesis of BPH. Vital et al. [45] measured levels of 8-OHdG in prostate tissues from normal transition zone or hyperplastic transition zone (BPH) taken from radical prostatectomies. 8-OHdG was also detected in tissues by immunohistochemistry and staining quantitated by image analysis. As NOX 4 promotes the formation of ROS, they created and characterised transgenic mice with prostate-specific expression of NOX 4 under the control of the prostate specific ARR2PB promoter. They found that human BPH tissues contained significantly higher levels of 8-OHdG than control transition zone tissues and the levels of 8-OHdG were correlated with prostate weight. Cells with 8-OHdG staining were predominantly in the epithelium and were present in a patchy distribution. The total fraction of epithelial staining with 8-OHdG was significantly increased in BPH tissues as studied by image analysis. The ARR2PB-NOX 4 mice had increased oxidative DNA damage in the prostate, increased prostate weight, increased epithelial proliferation, and histological changes including epithelial proliferation, stromal thickening, and fibrosis when compared to wild-type controls. It was concluded that oxidative stress and oxidative DNA damage are important in the pathogenesis of BPH. However, the presented findings show indications of oxidative stress when BPH changes are established, and thus it is still unclear whether oxidative stress and/or oxidative DNA damage are causative in the pathogenesis of BPH.
When assessing the importance of oxidative stress for LUT pathology and how oxidative stress should be treated, the general checklist presented by Murphy et al. [3] may be useful:
1. What is the specific ROS responsible? 2. Is the proposed reaction chemically plausible? 3. Is the ROS or antioxidant present at the appropriate location at a sufficient concentration to carry out the proposed reaction? 4. Does altering the amount of the particular ROS, or type of oxidative modification thought responsible, impact on the pathology or the redox signal?
Unfortunately, most of these points have not been investigated and discussed in studies linking oxidative stress and bladder pathology and the outcome of antioxidant therapy. To establish causality, e.g., that ROS is the main pathophysiological factor, it is not sufficient to only measure general markers of oxidative stress, e.g., MDA or 8-OHdG, or to measure activity of antioxidant systems (SOD, catalase). It has been emphasised that researchers should specify the particular ROS, and the reactions thought to be responsible for given biological effects, wherever possible and appropriate, and avoid vague usage of generic terms like ROS and antioxidant. Likewise, researchers should show that an antioxidant actually reacts with the particular ROS under discussion, and can, at least in principle, lower the concentration of that ROS sufficiently in vivo to explain its action [3] .
Conclusions
Oxidative stress has been suggested to be involved in a number of diseases, including LUT disorders. However, the clinical relevance of RONS is still largely unclear. To show a simple association between RONS production or a reduction of antioxidant systems, does not mean that RONS cause the disease, as association does not always mean causation. Most attempts to validate and exploit chronic antioxidant therapies have provided disappointing results. Identification of the specific ROS/RNS involved in the disease studied would be a reasonable basis for development of antioxidants with sufficient efficacy to be approved by health authorities.
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